Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon α-2b and ribavirin treatment for hepatitis C
Version of Record online: 18 SEP 2006
Volume 26, Issue 10, pages 1294–1297, December 2006
How to Cite
Alves Couto, C., Costa Faria, L., Dias Ribeiro, D., De Paula Farah, K., De Melo Couto, O. F. and De Abreu Ferrari, T. C. (2006), Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon α-2b and ribavirin treatment for hepatitis C. Liver International, 26: 1294–1297. doi: 10.1111/j.1478-3231.2006.01361.x
- Issue online: 18 SEP 2006
- Version of Record online: 18 SEP 2006
- Received 5 May 2006,accepted 14 August 2006
- focal segmental glomerulosclerosis;
- hepatitis C;
- nephrotic syndrome;
- pegylated interferon;
Abstract: Background: Interferon-α (IFN-α)and ribavirin combination therapy for chronic infection with hepatitis C virus produces a number of well-described side effects. Combination therapy with pegylated interferon (PEG-IFN) yields an adverse event profile similar to that observed with the standard IFN, although the frequency of certain adverse events may vary according to the preparation.
Case report: We report the case of a 44-year-old man who was treated with ribavirin and PEG-IFN-α-2b for chronic hepatitis C and developed two rare side effects simultaneously on the 16th week of therapy: severe thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis. The antiviral treatment was immediately interrupted and the patient received immunosuppressive therapy. He promptly recovered from the thrombocytopenia and partially and slowly from the nephrotic syndrome. To our knowledge, this is the first case reported of the development of such complications at the same time.